The main aim of the study is to find out whether the medicine is safe and can help shrink or control the cancer. Participants will be placed into different groups that receive the drug in one of the ways described, and they will have regular visits where doctors check for side effects, take blood samples, and perform imaging scans to see how the disease is responding. The study will follow each person for several months to monitor health and any changes in the cancer.

The purpose of this study is to learn how safe AZD4512 is and how well the body can tolerate it, and to find the right dose that can be used for treatment. The study will also look at how the medicine moves through the body, how it affects the disease, and whether the body’s immune system reacts to it. During the study, participants will receive the medicine through an infusion into a vein. Doctors will monitor participants closely by checking vital signs, doing blood tests, and using imaging scans such as PET scans and CT or MRI scans to see how the disease responds to treatment. These scans are special types of medical imaging that help doctors see inside the body and measure the size of lymphoma areas.

The study will track various aspects including any side effects that occur, how long any positive responses to treatment last, and how long participants live. Doctors will also measure the levels of the medicine in the blood and check if the body develops any immune responses to it. The response to treatment will be assessed using a specific classification system for lymphoma that looks at whether the cancer shrinks, stays the same, or grows during treatment. This is a phase one and phase two study, which means it is an early stage of testing to gather important information about the new treatment.

The purpose of this study is to test the safety of TdT-3 treatment and determine the most appropriate dose to use in future studies. Before receiving the cell therapy, patients will be given two medications called Fludarabine and Cyclophosphamide to prepare their body for the treatment. The treatment involves collecting the patient’s blood cells through a procedure called leukapheresis, processing these cells in a laboratory to create the TdT-3 therapy, and then giving the modified cells back to the patient.

During the study, doctors will closely monitor patients for any side effects and check how well the treatment works. They will take blood samples and perform various tests to track the modified cells in the body and measure the patient’s response to the treatment. The study will also look at how long the beneficial effects of the treatment last and whether patients can proceed to other treatments like stem cell transplantation if needed.

Participants in the study will receive CCS1477 in the form of a capsule taken by mouth. In some cases, it will be combined with other medications, such as Dexamethasone or Pomalidomide. The trial will monitor the safety and tolerability of these treatments, which means checking for any side effects and how well patients can handle the medication. The study will also look at how the drug is processed in the body and its potential effects on the cancer.

The trial will take place over several years, with regular check-ups and assessments to track the progress of the treatment. This includes looking at changes in the cancer through various tests and evaluations. The goal is to gather information on the drug’s safety and its impact on the cancer, which could help in developing new treatment options for these serious conditions.

The purpose of the study is to evaluate the safety and potential side effects of the HSP-CAR30 treatment. Participants will receive the treatment through an intravenous infusion, which means the medicine is given directly into a vein. The study will monitor participants closely for any side effects or reactions to the treatment. This will help researchers understand how the treatment works and how it affects the body.

In addition to HSP-CAR30, the study involves other medications that may be used in combination with the main treatment. These include Levact (bendamustine hydrochloride), Fludarabina Accord (fludarabine phosphate), Genoxal (cyclophosphamide monohydrate), and RoActemra (tocilizumab). These medications are also given through intravenous infusion and are used to help manage the cancer or support the immune system. The study will continue until the end of 2025, with participants being monitored throughout the process to gather important data on the treatment’s effectiveness and safety.

The study involves two specific treatments: AUTO1 and AUTO4, both of which are types of CAR T cell therapies. These treatments are given through an intravenous infusion, which means they are delivered directly into the bloodstream through a vein. Another treatment involved in the study is rituximab, known by the brand name MabThera, which is also given as an infusion. Rituximab is a medication that targets specific proteins on the surface of certain cells and is used in various conditions, including some types of cancer.

During the course of the study, participants will be monitored for any serious side effects related to the CAR T cell therapy, the development of new cancers, and other specific health events of interest. The study will also track overall survival rates and the duration of any supportive care needed. Additionally, researchers will look for any remaining genetic material from the therapy in the blood and check for any potential causes of new cancers. This follow-up will continue for up to 15 years after the initial CAR T cell therapy infusion.

The purpose of the study is to evaluate the safety and effectiveness of KTE-X19 in children and adolescents with these types of blood cancers. The study is divided into two phases. In the first phase, the focus is on assessing the safety of the treatment. In the second phase, the study aims to determine how well the treatment works in achieving remission, which means the cancer is no longer detectable. Participants will receive the treatment through an intravenous infusion, which is a method of delivering medication directly into the bloodstream.

Throughout the study, participants will be closely monitored for any side effects and to see how their cancer responds to the treatment. The study will also look at how long any remission lasts and overall survival rates. This research is important for understanding how effective KTE-X19 is in treating these challenging forms of cancer in young patients.

The purpose of this research is to determine the best dose and effectiveness of combining Brentuximab Vedotin with R-DHAP chemotherapy as a second-line treatment. The study is divided into two parts. The first part will establish the appropriate dose of the medication combination, while the second part will evaluate how well the treatment works.

During the study, participants will receive Brentuximab Vedotin through intravenous administration along with R-DHAP chemotherapy. The treatment will be given in cycles, and patients who respond well to the treatment may proceed to receive high-dose chemotherapy followed by autologous stem cell transplantation (a procedure where a patient’s own stem cells are used for treatment). The total treatment period may last up to 9 months.

The purpose of the study is to determine the appropriate dose of EO2463 and to assess its safety when used alone and in combination with Lenalidomide and Rituximab. The trial will be conducted in two phases. In the first phase, the focus will be on finding the right dose and ensuring the treatment is safe. In the second phase, the study will look at how well the treatment works in reducing the cancer according to specific criteria. Participants will receive EO2463 through an injection under the skin, and some may also receive Lenalidomide in capsule form or Rituximab through an infusion.

Throughout the study, participants will be monitored for any side effects and changes in their health. The trial aims to provide valuable information on the effectiveness and safety of EO2463, potentially offering a new treatment option for patients with Indolent Non-Hodgkin’s Lymphoma. The study is expected to continue until 2026, with ongoing assessments to ensure the well-being of participants and the collection of necessary data.

The trial includes a variety of medications, such as Rozlytrek, Cabometyx, Lenvima, Tepmetko, Retsevmo, Vectibix, Xalkori, Zejula, Tarceva, Inlyta, Pemazyre, Stivarga, Cotellic, Mekinist, Rubraca, Tecentriq, Keytruda, Tasigna, Erivedge, Talzenna, Sutent, Imfinzi, Avastin, Opdivo, Piqray, Lynparza, Zelboraf, Herceptin, Perjeta, Yervoy, Tafinlar, Lorviqua, and Vizimpro. Some of these drugs have code names, such as XL-184 for Cabometyx and LOXO-292 for Retsevmo. The study also involves the use of a placebo for comparison.

Participants in the study will receive one of these medications based on the specific characteristics of their cancer. The study will monitor the effects of the treatment over time, looking at how the cancer responds and any side effects that may occur. The goal is to better understand which drugs work best for different types of cancer and to provide patients with access to potentially effective treatments. The study is expected to continue until 2027, allowing researchers to gather comprehensive data on the long-term effects and benefits of these treatments.

The purpose of the study is to evaluate whether the risk of cancer returning in the central nervous system can be reduced by using dexamethasone instead of prednisone during the initial phase of treatment. Additionally, for patients at higher risk, the study will test if a more intensive treatment plan can improve the chances of staying cancer-free. This involves additional doses of PEG-asparaginase and a more intense course of treatment with methotrexate and other medications.

Participants in the study will receive treatment over a period of time, with some receiving the standard treatment and others receiving the experimental treatment. The study will monitor the participants to see how well the treatments work and if they help prevent the cancer from coming back. Some participants may receive a placebo as part of the study. The trial is designed to gather important information that could lead to better treatment options for children and adolescents with lymphoblastic lymphoma.

The study will monitor patients who continue taking tazemetostat either alone or in combination with other approved or experimental medications. During the study, researchers will track any side effects that may occur and how well patients tolerate the medication over an extended period. The medication will be provided according to each patient’s previous treatment plan.

Participants will be monitored for various health measures, including their blood cell counts, kidney function, and liver function. The study will also track how long patients survive while receiving the treatment. This is an open-label study, which means all participants will receive the active medication, and there is no use of a placebo.

The study aims to find out if using a medication called Levothyroxine can help reduce the risk of developing hypothyroidism after radiation therapy. Levothyroxine is a medication that helps to replace or supplement the hormones that the thyroid gland usually produces. In this study, some patients will receive Levothyroxine during their radiation treatment, while others will not, to see if it makes a difference in preventing hypothyroidism.

Participants in the study will be monitored for three years after their radiation therapy to check for signs of hypothyroidism. The goal is to determine if Levothyroxine can help protect the thyroid gland during radiation treatment and improve the long-term health of patients with these types of cancer. This research is important for finding better ways to manage the side effects of cancer treatments and improve the quality of life for patients.

The study is divided into different phases. In the first phase, patients will receive pirtobrutinib by itself to determine the best dose and to observe any side effects. In the second phase, the study will look at how well the drug works in reducing cancer symptoms. Additionally, there is a part of the study where pirtobrutinib is combined with other drugs like venetoclax and rituximab to see if these combinations are safe and effective. Patients will take the medication in the form of a tablet, which is taken by mouth.

Throughout the study, participants will be monitored for any changes in their health, including blood tests and other assessments to ensure their safety. The study aims to gather information on how the drug affects the body and how it interacts with other treatments. This research is important for developing new treatment options for patients with these types of blood cancers.

The purpose of this study is to evaluate the safety and effectiveness of this treatment combination in patients whose DLBCL has returned or has not responded to previous treatments. Participants in the study will receive the treatment over a period of up to 12 months. The study will monitor how well the treatment works and any side effects that may occur. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of the treatment.

Throughout the study, participants will have regular check-ups and tests to assess their response to the treatment. The study aims to provide valuable information on whether this combination of Tafasitamab and Lenalidomide can be a beneficial treatment option for patients with relapsed or refractory DLBCL. The results will help determine if this treatment can improve outcomes for patients with this challenging condition.

The purpose of this study is to gather information on the long-term safety of venetoclax for patients who have completed a previous trial involving this medication. Participants will continue to receive venetoclax, and their health will be monitored over time to collect data on any adverse events, which are any unwanted effects that may occur during the treatment. The study will involve taking venetoclax in the form of tablets, which are either dispersible or film-coated, and are taken orally.

Throughout the study, participants will be required to follow specific procedures and guidelines, especially those with Multiple Myeloma, who will need to take preventive antibiotics to reduce the risk of infections. The study is expected to continue until early 2026, allowing researchers to collect comprehensive safety data over an extended period. Participants will not be directly addressed or encouraged to join the study, as the information provided is purely informational.

Participants in the study will receive weekly injections of either Xembify or a placebo for a period of one year. The injections are given under the skin, a method known as subcutaneous injection. Throughout the study, researchers will monitor the participants to track the number of major bacterial infections they experience. The study aims to determine if Xembify can lower the rate of these infections compared to the placebo.

The trial will also look at other factors, such as how long it takes for the first major infection to occur, the total number of infections, and the number of days participants need antibiotics. Additionally, the study will record any hospitalizations due to infections. By gathering this information, researchers hope to better understand the potential benefits of Xembify for patients with these blood cancers and weakened immune systems.

The study aims to determine the most effective and safe dose of [90Y]Y-PentixaTher when used together with high-dose chemotherapy, followed by stem cell transplantation. The treatment approach targets a specific protein called CXCR4 that is found on cancer cells. Before receiving treatment, patients undergo special imaging tests to confirm whether their cancer cells have this protein.

The trial is conducted in two phases. In the first phase, different doses of the treatment will be tested to find the safest amount that can be given to patients. In the second phase, researchers will study how well the treatment works at the chosen dose. Throughout the study, patients will receive regular medical check-ups to monitor their response to treatment and any side effects that may occur.

Participants in the study will receive either the GnRHa treatment or a placebo, which is a substance with no active medication. The GnRHa treatment being studied is called Pamorelin, which is given as an injection. There are two different doses of Pamorelin being used in the study: 3.75 mg and 11.25 mg. The study will follow participants for several years to monitor their ovarian reserve and other health factors. This includes measuring levels of a hormone called Anti-Müllerian Hormone (AMH), which helps indicate the number of eggs left in the ovaries, at various points after the end of chemotherapy.

Throughout the study, participants will have regular check-ups to assess their ovarian reserve and overall health. This will involve tests like ultrasounds and blood tests to measure hormone levels. The study aims to provide valuable information on how GnRHa might help preserve fertility in young women and teenagers undergoing cancer treatment. By understanding the effects of this treatment, researchers hope to improve future care for patients facing similar challenges.